A Phase 2 interventional study of S-337395 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Shionogi. Recruiting at 89 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 44th largest by planned enrollment of the 122 interventional ones that give a count, is one of 8 that started in 2025, is one of 28 in phase 2, reaches primary completion later than 4 of the 13 other live ones, and was the 143rd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Pfizer · Sites in United States, Argentina, South Africa and 1 more country
Ages 0+ · Healthy volunteers
Clover Biopharmaceuticals USA, LLC · Sites in United States
Ages 60–85 · Healthy volunteers
Yale University · Sites in United States
Ages up to 12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 40 · Phase 3 29 · Phase 4 3
First in 1997; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 88 across the 122 interventional studies, 300 across the 23 observational. Of the 127 that completed or were terminated, 61 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 145 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 2 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Respiratory Syncytial Virus Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026749Phase 3University of Alabama at BirminghamAzithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | 2027-07-01 |
| NCT07214571ShionogiA Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | 2026-12-30 |
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
| NCT06686654Sanofi Pasteur, a Sanofi CompanyStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | 2027-01-18 |
| NCT06817889Fred Hutchinson Cancer CenterRemdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Key Inclusion Criteria:
Has at least 1 of the following risk factors for severe RSV disease:
Key Exclusion Criteria:
Note: Other protocol-specified inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a high dose of S-337395 twice daily (BID) orally for up to 5 days.
Drug: S-337395
Participants will receive a low dose of S-337395 BID orally for up to 5 days.
Drug: S-337395
Participants will receive matching placebo BID orally for 5 days.
Drug: Placebo
S-337395 will be administered per schedule specified in the arm description.
Placebo matched to S-337395 will be administered per schedule specified in the arm description.
Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2
Time frame: Baseline, Day 2
Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 4
Time frame: Baseline, Day 4
Change From Baseline in RSV RNA Load by qRT-PCR (Nasopharyngeal Swab) at Day 6
Time frame: Baseline, Day 6
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 1 up to Day 28
Change From Baseline in Severity of RSV Respiratory Symptom Score Based on the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Respiratory Symptom Subscale (RiiQ-RSS)
Time frame: Baseline up to Day 6
Change From Baseline in Severity of RSV Systemic Symptoms Score Based on the RiiQ Systemic Symptom Subscale (RiiQ-SSS)
Time frame: Baseline up to Day 6
Change From Baseline in Severity of RSV Total Symptoms Score Based on the Combined RiiQ RSS and RiiQ-SSS
Time frame: Baseline up to Day 6
Time to First Resolution of All Respiratory RSV-related Symptoms Based on the RiiQ-RSS
Time frame: Baseline up to Day 6
Time to Sustained (2 Consecutive Days) Resolution of All Respiratory RSV-related Symptoms Based on the RiiQ-RSS
Time frame: Baseline up to Day 6
Time to First Resolution of All Systemic RSV-related Symptoms Based on the RiiQ-SSS
Time frame: Baseline up to Day 6
Time to Sustained Resolution of All Systemic RSV-related Symptoms Based on the RiiQ-SSS
Time frame: Baseline up to Day 6
Time to First Resolution of All Respiratory and Systemic RSV-related Symptoms Based on the Combined RiiQ RSS and RiiQ-SSS
Time frame: Baseline up to Day 6
Time to Sustained Resolution of All Respiratory and Systemic RSV-related Symptoms Based on the Combined RiiQ RSS and RiiQ-SSS
Time frame: Baseline up to Day 6
Time to First Resolution of Each Separate RSV-related Symptom Based on the RiiQ Symptom Subscale
Time frame: Baseline up to Day 6
Time to Sustained Resolution of Each Separate RSV-related Symptom Based on the RiiQ Symptom Subscale
Time frame: Baseline up to Day 6
Change From Baseline in RSV RNA Load
Time frame: Baseline up to Day 6
Area Under the Curve (AUC) of Change From Baseline in RSV RNA Load
Time frame: Baseline up to Day 6
Time to the First Negative RSV RNA Load by qRT-PCR
Time frame: Baseline up to Day 6
Time to Sustained Negative RSV RNA Load by qRT-PCR
Time frame: Baseline up to Day 6
Percentage of Participants With Negative RSV RNA Load by qRT-PCR
Time frame: Baseline up to Day 6
Time to the First RSV RNA Load <Lower Limit of Quantitation (LLOQ)
Time frame: Baseline up to Day 6
Time to Sustained RSV RNA Load <LLOQ
Time frame: Baseline up to Day 6
Percentage of Participants With RSV RNA Load <LLOQ
Time frame: Baseline up to Day 6
Change From Baseline in Infectious Titer
Time frame: Baseline up to Day 6
AUC of Change From Baseline in Infectious Titer
Time frame: Baseline up to Day 6
Time to the First Negative RSV Infectious Titer
Time frame: Baseline up to Day 6
Time to Sustained Negative RSV Infectious Titer
Time frame: Baseline up to Day 6
Percentage of Participants With Negative RSV Infectious Titer
Time frame: Baseline up to Day 6
Time to the First RSV Infectious Titer <LLOQ
Time frame: Baseline up to Day 6
Time to Sustained RSV Infectious Titer <LLOQ
Time frame: Baseline up to Day 6
Percentage of Participants With RSV Infectious Titer <LLOQ
Time frame: Baseline up to Day 6
Plasma Concentration of S-337395 After Repeated Oral Doses of S-337395
Time frame: Baseline up to Day 6
Plasma Concentration of S-337395 12 and 24 Hours After the First Dose and the Last Dose (C12 and C24)
Time frame: 12 hours and 24 hours after first dose (Day 2) and last dose (Day 6)
Not enrolling at this site — choose another above.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 12 months is close to that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →